Seattle Genetics and Astellas file bladder cancer drug in USSeattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced Share XSeattle Genetics and Astellas file bladder cancer drug in UShttps://pharmaphorum.com/news/seattle-genetics-and-astellas-file-bladder-cancer-drug-in-us/
Why pharma needs honest patient dialogueAstellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the Share XWhy pharma needs honest patient dialoguehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/astellas-pharma-percival-barretto-ko/
Deep Dive: Oncology and ASCO 2019Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this Share XDeep Dive: Oncology and ASCO 2019https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Trial could unlock new prostate cancer sales for Pfizer/Astellas’ XtandiPfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but Share XTrial could unlock new prostate cancer sales for Pfizer/Astellas’ Xtandihttps://pharmaphorum.com/news/trial-prostate-cancer-pfizer-astellas-xtandi/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
Astellas gains three cancer drugs with $405m Potenza buyAstellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three Share XAstellas gains three cancer drugs with $405m Potenza buyhttps://pharmaphorum.com/news/astellas-gains-three-cancer-drugs-with-405m-potenza-buy/
Astellas scores first US blood cancer approval with XospataThe FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug Share XAstellas scores first US blood cancer approval with Xospatahttps://pharmaphorum.com/news/astellas-scores-first-us-blood-cancer-approval-with-xospata/
